Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Hepatitis B Immune Globulin Articles

Cangene gets orphan status for HepaGam

7 April 2008

Germany's Biotest buys Nabi unit for $185M

17 September 2007

FDA clears Cangene's HepaGam B for HBV

16 April 2007

Cangene's HepaGam gets US approval

6 February 2006

Cangene's HepaGam gets US approval

6 February 2006

Nabi's 3rd-qtr 2004 profit takes a dive

25 October 2004

Bayer Biologicals moves to stop counterfeiting

26 July 2004

FDA responds to Nabi's BLA for Nabi-HB

16 June 2003

Bayer retains Canadian blood products supply deal

6 January 2003

Nabi Files IND In USA For Hep B Drug

14 December 1998

Nabi Files IND with FDA For Reformulated Hepatitis B Immune Globulin

19 November 1998

Nabi's H-BIG Gets Priority Review Status From FDA

22 September 1998

Nabi Submit PLA For H-BIG

20 August 1998

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS